TCTR20180723001尚未招募未知
Bioequivalence Study of 100 mg sitagliptin Film-coated Tablets in Healthy Thai Volunteers
All Research Co., Ltd.0 个研究点目标入组 28 人开始时间: 2018年7月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy Thai male and female volunteers aged between 18 and 55 years.
- •2.The Body Mass Index (BMI) ranges from 18 to 25 kg/m2.
- •3.Determined healthy by medical history, physical examination and vital signs
- •4.The results of the clinical laboratory tests are within clinically acceptance limits i.e., blood urea nitrogen (BUN), serum creatinine, AST, ALT, total bilirubin, alkaline phosphatase, blood potassium, sodium, calcium, chloride, fasting blood sugar and hematology examinations including differential blood counts and HBsAg test. Some of the clinical laboratory values that out of the normal range will be carefully considered by clinical investigator.
- •5.Male volunteers who are surgically sterile or agree to use an effective contraception throughout the study and until the completion of the study.
排除标准
- •1.History or evidence of allergy or hypersensitivity to sitagliptin or any of the excipients of this product or any related drugs.
- •2.History or evidence of allergy or hypersensitivity to heparin.
- •3.History or evidence of hypertension (systolic BP >140 mmHg, diastolic BP > 90 mmHg) or hypotension (systolic BP <90 mmHg, diastolic BP <60 mmHg).
- •4.History or evidence of gastrointestinal, hepatic, renal, cardiovascular, hemato-logical disease or allergic disease or bronchial asthma or any disease that may affect the bioavailability of drug.
- •5.ECG results show malignant arrhythmia, or QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening or HR <40 bpm, or HR > 110 bpm. If QTc exceeds 450 msec, or QRS exceeds 120 msec, two more ECG tests must be performed and the average of the three QTc or QRS values should be used to determine the subject’s eligibility.
- •6.History of chronic or debilitating diseases.
- •7.Positive HBsAg tests.
- •8.History of alcoholism or drug abuse.
- •9.Positive urine drug abuse tests (Benzodiazepines, Methamphetamine and Opi-ates).
- •10.History of regular alcohol consumption (more than 1 time a week) or alcohol consumption within 7 days prior to the study drug administration and until the completion of the study.
- •11.History of smoking more than 10 cigarettes/day, or moderate smokers (less than 10 cigarettes/day) and could not quit at least 7 days prior to the study drug administration and until the completion of the study.
- •12.Tea/coffee or caffeine- or xanthine-containing beverage consumption within 7 days prior to the study drug administration and until the completion of the study.
- •13.Grapefruit juice or grapefruit-containing products consumption within 7 days prior to the study drug administration and until the completion of the study.
- •14.Use of any prescription drugs or over-the-counter (OTC) drugs or herbal medi-cines within 30 days or vitamins or food supplements within 14 days prior to the study drug administration or use hormonal methods of contraception with-in 28 days (discontinuation for at least 6 months is required for Depo-Provera use) prior to receiving the first dose of the study medication and until the com-pletion of the study.
- •15.Blood donation or blood loss over 350 mL within 90 days preceding the admission into the study.
- •16.Participation in any clinical studies within 90 days preceding the admission into this study.
研究者
相似试验
尚未招募
1 期
Bioequivalence study of sitagliptin 100 mg film-coated tablet in Thai healthy volunteersThai healthy male and female subjects , Aged 18 to 50 years , BMI were within 18-25 kg/m2 , Good health confirming by physical and clinical.HealthyTCTR20210824012Faculty of Medicine, Chulalongkorn University26
尚未招募
不适用
Comparative in vivo evaluation of 2 Sitagliptin 100 mg Tablet formulationsIRCT20180620040164N27Actover Pharmaceutical Co.24
尚未招募
不适用
Bioequivalence Study of 5 mg Linagliptin Film-coated Tablets in Healthy Thai VolunteersBioequivalence of generic linagliptin 5 mg film-coated tabletsTCTR20180213002All Research Co., Ltd.36
已完成
不适用
Bioequivalence study of alogliptin 25 mg film-coated tablet under fasting condition in healthy volunteerBioequivalence study of alogliptin 25 mgBioequivalence study of alogliptin 25 mg film-coated tablet under fasting condition in healthy volunteerTCTR20200227002nison Laboratories Co., Ltd.30
尚未招募
不适用
igagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.IRCT20200105046010N8Tabriz University of Medical Sciences24